Neuronetics Amends Credit Agreement and Revenue Covenants

Neuronetics (STIM) amended its credit agreement with Perceptive Credit Holdings, modifying revenue covenants. The amendment requires a $15M prepayment by November 30, 2026, or automatic termination. Analysts rate STIM as Buy with a $6.00 target, while TipRanks' AI rates it Neutral due to financial weaknesses, though recent earnings show improvement.

Original reporting
Published Nov 10, 2026, 9:37 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 10, 2026, 10:31 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$STIM
Bearish
medium confidence
Mentioned
$STIM
Relevance
5/10
AlphAI data visualization · based on tipranks.com
Decision brief

The 30-second read

$STIMBearishLow
01

Why it matters

The amendment signals tighter financial oversight, which could pressure the share price unless the company demonstrates improved cash generation.

02

Market read

A micro‑cap credit amendment with new covenants is a modest but material corporate action for traders monitoring STIM.

03

What to watch

Potential for a future refinancing at better rates if cash flow improves; the $15M optional prepayment may be unused.

Relevance 5/10Novelty 5/10Timing: today

Background

Neuronetics (STIM) provides FDA‑cleared neurostimulation devices for depression treatment. The company has been trading below $10 with high leverage.

Company-level read

Ticker impact

$STIMBearishMedium confidence
Context

Neuronetics amended its credit agreement (Amendment No. 6) adding revenue covenants and a $15M optional prepayment clause.

Expected impact

likely downside as investors price in covenant risk and higher leverage concerns

Evidence & confidence

Covenant tightening and optional prepayment requirements signal cash flow pressure for a micro‑cap with negative free cash flow.

Market effects

May raise scrutiny on other small‑cap med‑tech firms with similar credit structures.

Limited to U.S. listed micro‑caps; no broader regional effect.

Minimal; confined to niche neuro‑stimulation market.

Counterpoint

If the company can meet the new covenants, the amendment could improve credit terms and support the stock.

Key entities

  • Neuronetics

    U.S. listed neurostimulation device maker (ticker STIM).

  • Perceptive Credit Holdings IV, LP

    Administrative agent and lender for the credit agreement.

Related articles

$STIMHigh

Why is Neuronetics stock tumbling today?

Neuronetics Inc's stock fell 11.4% in pre-market trading after pricing a $30M share offering at a discount. The company aims to use proceeds to address going concern risks and meet a $15M loan prepayment deadline by November 30, 2026. Despite Q3 revenue growth, these factors drove the decline, with no broader market impact.

$STIMHigh

Neuronetics stock tumbles 10% on stock offering launch

Neuronetics Inc (STIM) shares dropped 10% in after-hours trading after announcing a public stock offering and a credit agreement amendment. The company aims to sell shares with a 30-day option for underwriters to buy 15% more. The amendment reduces revenue covenants if certain conditions are met by November 30, 2026, addressing going concern risks. William Blair, BTIG, and Canaccord Genuity are managing the offering.

$STIMHigh

Neuronetics Inc (STIM) (Q3 2026) Earnings Call Highlights: Revenue Jumps

Neuronetics Inc (STIM) reported Q3 2026 revenue of $42M, up 12.5% YoY, driven by Greenbrook's 20.1% growth. Gross margin expanded to 52.2%, and operating expenses decreased 12.6%, leading to positive adjusted EBITDA of $1.9M. NeuroStar revenue grew only 1.8% YoY, with session revenue declining. Cash balance decreased to $27.9M. Management expects full-year 2026 cash flow to be negative $10M to $12M.

$STIMMed

Neuronetics Q3 Earnings Call Highlights

Neuronetics reported Q3 revenue growth driven by record system sales, with capital and lease units making up over half of sales. The company expects lower treatment-session revenue as it shifts focus to larger customers. Neuronetics anticipates higher growth in 2027 and beyond. It also submitted a 510(k) application for an accelerated TMS protocol and cited a study showing treatment gaps do not reduce effectiveness.